ClinicalEU

EU Medical Device Regulation (MDR) 2017/745 Clinical Evaluation Overview

Build a defensible clinical evidence strategy and CER.

Connect clinical evaluation to intended purpose, risk management, GSPR, PMS/PMCF, and change control so updates don't break compliance.

Back to main artifact Review sources

Author

Sorena AI

Published

Feb 22, 2026

Updated

Feb 22, 2026

Sections

Structured answer sets in this page tree.

Primary sources

Cited legal and guidance references.

Publication metadata

Sorena AI

Published Feb 22, 2026

Updated Feb 22, 2026

Overview

Under MDR, clinical evaluation is a lifecycle process: you justify safety and performance for the intended purpose using clinical data, you document the reasoning, and you update it when risks, claims, technology, or post-market signals change. Teams get stuck when clinical evaluation is treated as a document at the end rather than a system that drives product decisions.

Section 1

What clinical evaluation is (and what it is not)

Clinical evaluation is the structured assessment of clinical data to verify that the device achieves its intended performance and that risks are acceptable relative to benefits for the target population.

It is not a marketing story. It's a traceable argument that links intended purpose and claims to data quality, clinical relevance, and residual risk acceptability.

Clinical evaluation and risk management must agree: hazards, clinical risks, and residual risks must match across documents.
GSPR checklist (Annex I) should link to clinical evidence for claims and for risk/benefit justification where relevant.
If you ship software updates, your change control must include clinical impact assessment triggers.

Section 2

Step-by-step workflow you can execute

A high-quality CER is the output of a repeatable workflow. Use the steps below as gates: do not write the CER until you can pass each gate.

Output: clinical evaluation plan (CEP) + CER + update plan.

Define intended purpose and claims precisely (including performance claims shown in UI outputs).
Define clinical benefits, endpoints, and acceptability thresholds; document the current state of the art
Identify clinical risks and benefit-risk questions that evidence must answer.
Select clinical data sources and inclusion/exclusion criteria; plan evidence gaps and mitigations.
Appraise clinical data quality and relevance; synthesize conclusions; document limitations and residual uncertainties.

Section 3

Clinical data strategy: what counts as sufficient clinical evidence

Your evidence strategy should be explicit: which data sources you rely on (and why), what you will collect post-market, and what triggers you to refresh the evaluation.

Practical rule: if you can't explain why the data is representative of your device, indications, and users, it won't survive scrutiny.

Clinical investigations: highest signal, but expensive; plan early if needed.
Literature and existing clinical experience: works best when device and use context are truly comparable and claims are modest.
Real-world evidence and PMS data: necessary for lifecycle updates; treat data quality as a regulated output.
PMCF: use when residual uncertainty remains or when required by class/device type; define how PMCF closes specific evidence gaps.

Section 4

Equivalence is a strategy - but you must prove it (don't hand-wave)

Equivalence is often misunderstood. If you claim equivalence, you need a structured, auditable demonstration that the comparable device truly matches your device in the relevant ways for the intended purpose and clinical claims.

Control: write an equivalence dossier that is versioned and tied to change control.

Define equivalence criteria (technical, biological, clinical) and show how you meet them.
Prove access to sufficient data about the equivalent device; public info often isn't enough.
Re-run equivalence analysis when design, materials, software algorithms, or indications change.

Section 5

Common failure modes (use these as review questions)

Use these questions to pre-review your CER and reduce rework with notified bodies and internal stakeholders.

If you can't answer a question in one paragraph with evidence links, your CER likely needs more work.

Do the intended purpose and clinical claims match the label/IFU, UI outputs, and marketing materials exactly?
Is the clinical data appraisal method explicit and repeatable (not a vague statement that some papers were reviewed)?
Are limitations and residual uncertainties documented, with planned PMCF/PMS actions where needed?
Do risk management conclusions align with clinical conclusions (no contradictions)?
Are update triggers defined for software updates, new indications, new populations, or post-market signals?

Recommended next step

Use EU Medical Device Regulation (MDR) 2017/745 Clinical Evaluation Overview as a cited research workflow

Research Copilot can take EU Medical Device Regulation (MDR) 2017/745 Clinical Evaluation Overview from getting cited answers and faster research on this topic to a reusable workflow inside Sorena. Teams working on EU Medical Device Regulation (MDR) 2017/745 can keep owners, evidence, and next steps aligned without copying this guide into separate documents.

Research workflow

Open Research Copilot for EU Medical Device Regulation (MDR) 2017/745 Clinical Evaluation Overview

Start from EU Medical Device Regulation (MDR) 2017/745 Clinical Evaluation Overview and answer scope, timing, and interpretation questions with cited outputs.

Explore next step

Talk to Sorena

Talk through EU Medical Device Regulation (MDR) 2017/745

Review your current process, evidence gaps, and next steps for EU Medical Device Regulation (MDR) 2017/745 Clinical Evaluation Overview.

Explore next step

Primary sources